Results Bolster Tysabri for Multiple Sclerosis

Research results disclosed at the American Academy of Neurology reveal that over two years Biogen/Elan's Tysabri was about twice as effective as existing therapries in reduceing multiple sclerosis flare-ups and was slightly better in reducing disease progression.  Such results revive hope the drug, withdrawn from the market earlier this year after two, and later a third, clinical trial patient died, will return to the market.

Associated Press